Levonadifloxacin

DB16219InvestigationalSmall molecule

Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).

Chemical structure of Levonadifloxacin
Mechanism
Curator reviewed
Formula / weight
C19H21FN2O4 · 360.385 g/mol (avg)
Also known as
(s)-(-)-nadifloxacin · Nadifloxacin, (s)- · Wck 771 free base · Wck-771 free base · Wck771 free base

Resolves to

Compound
UNII8WHH66L098CAS154357-42-3ChEMBLCHEMBL190561ChEBI37908
Clinical / RWD
ATCJ01MA24
Structure
InChIKeyJYJTVFIEFKZWCJ-JTQLQIEISA-NSMILESC[C@H]1CCC2=C(N3CCC(O)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Targets
P0A0K8gyrBP0C1U9parCP20831gyrA

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Levonadifloxacin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In